A novel administration route for edaravone: I. Effects of metabolic inhibitors on skin permeability of edaravone

International Journal of Pharmaceutics

Volumn 372, Issue 1-2, 2009, Pages 33-38

  Sato, Toshiaki ^a   Mizuno, Keizo ^a   Ishii, Fumiyoshi ^b  

^a Research and Development Division   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Benzotriazole; Edaravone; Hairless rat; Hydroxypropyl cyclodextrin; l Cysteine; Skin

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BENZOTRIAZOLE DERIVATIVE; CYSTEINE; DICLOFENAC; INDOMETACIN; NORPHENAZONE; PROADIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG INHIBITION; DRUG PENETRATION; DRUG POTENTIATION; DRUG RETENTION; DRUG STABILITY; HAIRLESS RAT; MALE; NONHUMAN; PRIORITY JOURNAL; SKIN PERMEABILITY; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIPYRINE; MALE; PERMEABILITY; PROADIFEN; RATS; RATS, HAIRLESS; SKIN ABSORPTION;

EID: 64149126571     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.12.038     Document Type: Article

References (26)

1. Arii K., Kumon Y., Ikeda Y., Suehiro T., and Hashimoto K. Edaravone inhibits rheumayoid synovial cell proliferation and migration. Free Radic. Res. 40 (2006) 121-125
2. Arii K., Kumon Y., Ikeda Y., Suehiro T., and Hashimoto K. Edaravone inhibits the disease activity in rheumatoid arthritis. J. Clin. Pharm. Ther. 31 (2006) 197-199
3. Babu R.J., Kikwai L., Jaiani L.T., Kanikkannan N., Armstrong C.A., Ansel J.C., and Singh M. Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: Spantide II. Pharm. Res. 21 (2004) 108-113
4. Cimen M.Y., Cmen O.B., Kacmaz M., Ozturk H.S., Yorgancioglu R., and Durak I. Oxidant/antioxidant status of the erythrocytes from patients with rheumatoid arthritis. Clin. Rheumatol. 19 (2000) 275-277
5. Fukudome D., Matsuda M., Kawasaki T., Ago Y., and Matsuda T. The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice. Eur. J. Pharmacol. 583 (2008) 164-169
6. Kuehl G.E., Lampe J.W., Potter J.D., and Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab. Dispos. 33 (2005) 1027-1035
7. Haseloff R.F., Blasig I.E., Meffert H., and Ebert B. Hydroxyl radical scavenging and antipsoriatic activity of benzoic acid derivatives. Free Radic. Biol. Med. 9 (1990) 111-115
8. Hayashi S., Yasui H., and Sakurai H. Essential role of singlet oxygen species in cytochrome P450-dependent substrate oxygenation by rat liver microsomes. Drug Metab. Pharmacokinet. 20 (2005) 14-23
9. Houkin K., Nakayama N., Kamada K., Noujou T., Abe H., and Kashiwaba T. Neuroprotective effect of the free radical scavenger MCI-186 in patients with cerebral infarction: clinical evaluation using magnetic resonance imaging and spectroscopy. J. Stroke Cerebrovasc. Dis. 7 (1998) 315-322
10. Kawai H., Nakai H., Suga M., Yuki S., Watanabe T., and Saito K.I. Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther. 281 (1997) 921-927
11. Komatsu T., Nakai H., Takamatsu Y., Morinaka Y., Watanabe K., Shinoda M., and Iida S. Pharmacokinetic studies of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186): metabolism in rats, dog and human. Drug Metab. Pharmacokinet. 11 (1996) 451-462
12. Mazzetti I., Grigolo B., Pulsatelli L., Pulsatelli L., Dolzani P., Silvestri T., Roseti L., Meliconni R., and Facchini A. Differential roles of nitric oxide and oxygen radicals in chondrocytes affected by osteoarthritis and rheumatoid arthritis. Clin. Sci. (Lond.) 101 (2001) 593-599
13. Miesel R., Murphy M.P., and Kroger H. Enhanced mitochondrial radical production in patients with rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic. Res. 25 (1996) 161-169
14. Okayama Y. Oxidative stress in allergic and inflammatory skin diseases. Curr. Drug Targets Inflamm. Allergy 4 (2005) 517-519
15. Ozturk H.S., Cimen M.Y., Cimen O.B., Kacmaz M., and Durak I. Oxidant/antioxidant status of plasma sample from patients with rheumatoid arthritis. Rheumatol. Int. 19 (1999) 35-37
16. Prasad K., and Laxdal V.A. Hydroxyl radical-scavenging property of indomethacin. Mol. Cell. Biochem. 136 (1994) 139-144
17. Sato T., Mizuno K., and Ishii F. Effects of various cyclodextrins on solubility and penetration through the synthesized membrane of edaravone. Mater. Technol. 23 (2005) 403-408
18. Sato T., Mizuno K., and Ishii F. Effects of hydroxypropyl-β-cyclodextrin on the transdermal delivery of edaravone through hairless rat skin. Mater. Technol. 24 (2006) 79-84
19. Sato T., Mizuno K., and Ishii F. In vitro metabolism study of edaravone in Wistar and hairless rat skin. Biol. Pharm. Bull. 31 (2008) 1150-1154
20. Sueishi K., Mishima K., Makino K., Itoh Y., Tsuruya K., Hirakata H., and Oishi R. Eur. J. Pharmacol. 451 (2002) 203-208
21. Towner R.A., Mason R.P., and Reinke L.A. In vivo detection of aflatoxin-induced lipid free radicals in rat bile. Biochim. Biophys. Acta 1573 (2002) 55-62
22. Watanabe T., Yuki S., Egawa M., and Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther. 268 (1994) 1597-1604
23. Watanabe T., Morita I., Nishi H., and Murota S. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot. Essent. Fatty Acids 33 (1988) 81-87
24. Watanabe T., Tanaka M., Watanabe K., Takamatsu Y., and Tobe A. Research and development of the free radical scavenger edaravone as neuroprotectant. Yakugaku Zasshi 124 (2004) 99-111
25. Yamamoto T., Yuki S., Watanabe T., Mitsuka M., and Saito K. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res. 762 (1997) 240-242
26. Yoshino H., and Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph. Lateral Scler. 7 (2006) 241-245